Over the last 30 years, genetically engineered DNA has been tested as novel vaccination strategy against various diseases, including human immunodeficiency virus (HIV), hepatitis B, several parasites, and cancers. However, clinical breakthrough of technique is confined by low transfection efficacy immunogenicity employed vaccines. Therefore, carrier materials were designed to prevent rapid degr...